PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department

NCT ID: NCT07086560

Last Updated: 2025-08-03

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 20 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-04-04
• Study Completion Date: 2026-12-31

Brief Summary

Supraventricular tachycardia (SVT) is a dysrhythmia characterized rapid heart rate, typically with rapid onset. SVT accounts for over 50,000 emergency department visits per year. Of patients with regular, narrow-complex SVT, the mainstay of therapy includes adenosine and diltiazem. Adenosine is recommend by American and European guidelines as first-line therapy, however adenosine carries unique side effects that are potentially distressing to patients, including: "feeling of impending death or doom", flushing, anxiety, shortness of breath, and chest discomfort. Diltiazem does not carry this side effect profile, but has typically been reserved as second-line treatment due to side effects of low blood pressure associated with this class of medications. Diltiazem and adenosine have not been well studied head-to-head to compare safety and efficacy of their treatment for SVT. The purpose of this study is to evaluate safety and efficacy of adenosine and diltiazem for SVT in the ED (as completed through chart review of specific patient-level outcomes) and capture patient and clinician perspectives of medication satisfaction (through administration of questionnaires).

Conditions

Supraventricular Tachycardia (SVT)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Adenosine

IV adenosine

Intervention Type: DRUG

Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment

Diltiazem

IV diltiazem

Intervention Type: DRUG

Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment

Interventions

IV adenosine

Patients will not be randomized to intervention but will be categorized based on the exposure of IV adenosine for treatment of SVT received prior to study enrollment

Intervention Type: DRUG

IV diltiazem

Patients will not be randomized to intervention but will be categorized based on the exposure of IV diltiazem for treatment of SVT received prior to study enrollment

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. ED encounter for acute SVT

2. Age >/= 18 years

3. Receipt of IV adenosine and/or IV diltiazem for SVT in the ED or prehospital setting

Exclusion Criteria

1. Neurologic status precluding survey participation due to medical instability

2. Pregnant

3. Incarcerated

4. Non-English speaking

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Iowa

OTHER

Sponsor Role: lead

Responsible Party

Anne E. Zepeski

Clinical Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Iowa Health Care

Iowa City, Iowa, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Anne Zepeski, PharmD

Role: CONTACT

anne-zepeski@uiowa.edu

651-207-9357

Facility Contacts

Anne Zepeski

Role: primary

anne-zepeski@uiowa.edu

651-207-9357

Other Identifiers

202411431

Identifier Type: -

Identifier Source: org_study_id